塞力医疗: 2025年半年度报告摘要

Core Viewpoint - The report indicates a significant decline in the financial performance of Celis Medical Technology Group Co., Ltd. for the first half of 2025, with substantial decreases in revenue and net profit compared to the previous year [1]. Financial Summary - Total assets at the end of the reporting period were approximately ¥2.199 billion, a decrease of 22.30% from the previous year-end [1]. - Operating revenue for the reporting period was approximately ¥583.5 million, reflecting a decline of 40.20% compared to the same period last year [1]. - Total profit for the period was approximately -¥51.93 million, representing a decrease of 495.76% from the previous year [1]. - Net profit attributable to shareholders was approximately -¥56.12 million, with no comparable figure provided for the previous year [1]. - The net cash flow from operating activities was approximately -¥79.17 million, compared to -¥48.88 million in the same period last year [1]. - The weighted average return on net assets decreased by 6.3 percentage points to -6.73% [1]. - Basic and diluted earnings per share were both approximately -¥0.2938, with no prior year comparison available [1]. Shareholder Information - As of the end of the reporting period, the total number of shareholders was 45,698 [2]. - The largest shareholder, Shanghai Saihai Health Technology Co., Ltd., holds 11.33% of shares, amounting to 21,642,540 shares, with 15,800,000 shares pledged [2]. - Other significant shareholders include Shanghai Anze Private Fund Management Co., Ltd. and individual shareholders, with varying percentages and share amounts [2].